Primary central nervous system (CNS) lymphoma or systemic non-Hodgkin lymphoma that infiltrates the CNS can cause central diabetes insipidus (CDI). Polyuria and polydipsia should raise the suspicion of CDI development in patients with lymphoma that infiltrates the CNS. CDI is effectively treated with desmopressin. However, careful monitoring of the patient's serum sodium, fluid intake, urine output, and weight is necessary because patients receiving desmopressin may develop hyponatremia, so they should be alert to recognize this side effect promptly. Moreover, CDI due to lymphoma can occasionally be reversible. Therefore, the dosage of desmopressin should be adapted during or after the treatment of lymphoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404345 | PMC |
| http://dx.doi.org/10.7759/cureus.41500 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatic and Pancreatic Cellular Response to Early Life Nutritional Mismatch.
Endocrinology
January 2025
Department of Pediatrics, Divisions of Neonatology & Developmental Biology and Endocrinology, Neonatal Research Center of the UCLA Children's Discovery & Innovation Institute at the David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1752.
To determine the basis for perinatal nutritional mismatch causing metabolic dysfunction associated steatotic liver disease (MASLD) and diabetes mellitus, we examined adult phenotype, hepatic transcriptome, and pancreatic β-islet function. In prenatal caloric restricted rat with intrauterine growth restriction (IUGR) and postnatal exposure to high fat with fructose (HFhf) or high carbohydrate (RC), we investigated male and female IUGR-Hfhf and IUGR-RC, versus HFhf and CON offspring. Males more than females displayed adiposity, glucose intolerance, insulin resistance, hyperlipidemia, hepatomegaly with hepatic steatosis.
View Article and Find Full Text PDFAnalysis of the efficacy of lactulose combined with polyethylene glycol in the treatment of functional constipation.
Am J Transl Res
December 2024
Anorectal Department, Suining Central Hospital Suining 629000, Sichuan, China.
Objectives: This study focuses on analyzing the efficacy of lactulose oral solution combined with Macrogol 4000 Powder in the treatment of functional constipation (FC).
Methods: A total of 125 FC patients were selected, with 60 cases in a control group, who were treated with lactulose oral solution alone, and 65 cases in a research group, who were treated with lactulose oral solution combined with Macrogol 4000 Powder. The two groups were analyzed and compared in terms of efficacy, symptom recovery, Bristol Stool Form Scale (BSFS) and Wexner Constipation Scale (WCS) scores, adverse effects, serum indices, and Patient Assessment of Constipation Quality of Life (PAC-QOL).
Emerging role of adaptive immunity in diabetes-induced cognitive impairment: from the periphery to the brain.
Metab Brain Dis
January 2025
National Key Laboratory of Chinese Medicine Modernization, Tianjin University of Traditional Chinese Medicine, Jinghai District, Tianjin, 301617, China.
Diabetic cognitive impairment (DCI) is a central nervous system complication induced by peripheral metabolic dysfunction of diabetes mellitus. Cumulative studies have shown that neuro-immune crosstalk is involved in the pathological progression of DCI. However, current studies mostly focus on the interaction between innate immunity cells and neurons, while ignoring the role of adaptive immunity cells in DCI.
View Article and Find Full Text PDFAutomated insulin delivery in pregnant women with type 1 diabetes: a systematic review and meta-analysis.
Acta Diabetol
January 2025
Department of Emergency, Tianjin Fifth Central Hospital (Peking University Binhai Hospital), Tianjin, 300450, China.
Aim: The outcomes of automated insulin delivery (AID) systems in pregnant women with type 1 diabetes (T1D) have not been systematically evaluated. This study aims to evaluate the efficacy and safety of AID in pregnancy.
Material And Methods: Literature searches were conducted until July 5, 2024, on Embase, PubMed, Cochrane Library, and ClinicalTrials.
Effectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study].
Drugs Real World Outcomes
January 2025
Department of Medical Affairs, Cipla Ltd., Mumbai Central, Mumbai, Maharashtra, 400008, India.
Background And Objective: Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in India. This study aimed to evaluate the effectiveness and tolerability of vildagliptin XR in patients with type 2 diabetes in real-world clinical settings.
Methods: This was an observational, prospective, multicenter, cohort study conducted in India, which included patients with type 2 diabetes uncontrolled on metformin XR monotherapy with glycated hemoglobin (HbA1c) > 7.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!